NOVELMED THERAPEUTICS, INC.

Address

11000 Cedar Avenue, 135
CLEVELAND, OH, 44106-3007

http://www.novelmed.com

Information

DUNS: 190155171
# of Employees: 12

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y

Award Charts




Award Listing

  1. Preclinical and Clinical Evaluation of Humanized NM9405

    Amount: $2,436,893.00

    DESCRIPTION provided by applicant NovelMed has developed an anti properdin antibody hNM for the treatment of intra and extravascular lysis in paroxysmal nocturnal hemoglobinuria PNH The se ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  2. Single Therapy for Wet AMD and Geographic Atrophy

    Amount: $548,724.00

    DESCRIPTION (provided by applicant): Approximately 85% of the total age-related macular degeneration (AMD) patients have the Dry form. Geographic atrophy (GA) is the advanced form of Dry AMD and is ca ...

    SBIRPhase I2014Department of Health and Human Services
  3. Preclinical and Clinical Evaluation of Humanized NM9405

    Amount: $467,832.00

    ABSTRACT NovelMed has developed an anti-properdin antibody (hNM9405) for the treatment of intra and extravascular lysis in paroxysmal nocturnal hemoglobinuria (PNH). The selection of this antibody was ...

    SBIRPhase I2014Department of Health and Human Services
  4. Alternative Pathway Inhibitors for Orphan Indication

    Amount: $889,438.00

    DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. I ...

    SBIRPhase II2014Department of Health and Human Services
  5. Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis

    Amount: $1,451,573.00

    DESCRIPTION provided by applicant NovelMed intends to develop a humanized anti Bb antibody as a prophylactic treatment for inflammatory responses associated with hemodialysis During this procedur ...

    SBIRPhase II2014Department of Health and Human Services
  6. Single Therapy for Wet AMD & Geographic Atrophy

    Amount: $588,124.00

    DESCRIPTION provided by applicant Approximately of the total age related macular degeneration AMD patients have the Dry form Geographic atrophy GA is the advanced form of Dry AMD and is ca ...

    SBIRPhase II2014Department of Health and Human Services
  7. Set2Read-AK (Alphabet Knowledge)

    Amount: $542,572.00

    DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. I ...

    SBIRPhase I2013Department of Health and Human Services
  8. Complement Inhibitors as DMOADs

    Amount: $307,870.00

    DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent amon ...

    SBIRPhase II2013Department of Health and Human Services
  9. Complement Inhibitors for Macular Degeneration

    Amount: $1,064,251.00

    DESCRIPTION (provided by applicant): According to the World Health Organization (WHO) global eye disease survey, 14 million people are blind or severely visually impaired due to age-related macular de ...

    SBIRPhase II2012Department of Health and Human Services
  10. Complement Inhibitors as DMOADs

    Amount: $294,766.00

    DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent amon ...

    SBIRPhase I2012Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government